ClinicalTrials.gg
CompletedNCT02101788Updated Aug 4, 2026Results posted

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

A Phase 2/3 interventional study of Letrozole and Paclitaxel in Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma and Ovarian Serous Adenocarcinoma, sponsored by National Cancer Institute (NCI). Completed at 501 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by National Cancer Institute (NCI) · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To estimate the progression-free survival (PFS) hazard ratio of trametinib compared to that of "commercially available therapies" consisting of one of five commercially available agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum previously treated with platinum-based chemotherapy.

SECONDARY OBJECTIVES:

I. To determine the nature, frequency and maximum degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 for each treatment arm.

II. To determine the quality of life, as assessed by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O).

IIa. To compare trametinib to the control arm with regard to patients' self-reported acute (up to post-cycle 6) quality of life as measured by the FACT-O-Trial Outcome Index (TOI).

IIb. To compare trametinib to the control arm with regard to patients' self-reported acute (up to post-cycle 6) neurotoxicity as measured by the FACT-Gynecologic Oncology Group (GOG)-Neurotoxicity (NTX).

III. To estimate the objective response rate (RR) of patients in each treatment arm.

IV. To test whether high expression of pERK, as quantified by immunohistochemistry (IHC), is associated with better prognosis (RR or PFS) among patients receiving the randomized treatment.

V. To test whether genetic changes associated with MAPK pathway activation (KRAS, NRAS, HRAS, BRAF, MEK, ERBB2 or NF1) are associated with improved prognosis (RR or PFS) among patients receiving the randomized treatment.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients receive clinician's choice of either letrozole orally (PO) once daily (QD) on days 1-28, tamoxifen citrate PO twice daily (BID) on days 1-28, paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride (PLD) IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.

ARM B: Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.

02

Conditions studied

  • Borderline Ovarian Serous Tumor
  • Micropapillary Serous Carcinoma
  • Ovarian Serous Adenocarcinoma
  • Primary Peritoneal Serous Adenocarcinoma
  • Recurrent Ovarian Low Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Serous Adenocarcinoma
03

In context

Cystadenocarcinoma, Serous

15 studies on the registry are indexed under Cystadenocarcinoma, Serous; 1 is open to participants now.

This study's enrollment of 260 is above the median of 52 across 13 interventional studies indexed under Cystadenocarcinoma, Serous.

Browse Cystadenocarcinoma, Serous studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age greater than 18 with the following tumors are included in the study:

    • Patients initially diagnosed with low-grade serous ovarian or peritoneal carcinoma that recur as low-grade serous carcinoma (invasive micropapillary serous carcinoma or invasive grade I serous carcinomas as defined by GOG, Federation of Obstetricians and Gynecologists [FIGO], World Health Organization [WHO] or Silverberg)
    • Patients initially diagnosed with serous borderline ovarian or peritoneal carcinoma that recur as low-grade serous carcinoma (invasive micropapillary serous carcinoma or invasive grade I serous carcinomas as defined by GOG, FIGO WHO or Silverberg)
  • At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g. MAJOR: laparotomy, laparoscopy, thoracotomy, VATS [video assisted thorascopic surgery]); there is no restriction on MINOR procedures: (e.g. central venous catheter placement, ureteral stent placement or exchange, tumor core or fine-needle aspirate [FNA] )
  • Patients must have documented low-grade serous carcinoma; confirmation must occur by prospective pathology review prior to study entry; the prospective pathology review can be done on tissue from the recurrent carcinoma or from original diagnostic specimen
  • All patients must have as defined by (RECIST) 1.1; measurable disease is defined as at least one target lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI; all imaging studies must be performed within 28 days prior to registration
  • Prior therapy

    • Patients must have recurred or progressed following at least one platinum-based chemotherapy regimen
    • Patients may have received an unlimited number of prior therapy regimens
    • Patients may not have received all of the five choices in the "standard therapy" arm
    • Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration
    • Any other prior therapy directed at the malignant tumor, including chemotherapy and radiation therapy, must be discontinued at least 4 weeks prior to registration; any agent must be discontinued at least 28 days prior to registration
  • Trametinib, can cause fetal harm when administered to a pregnant woman; women of (i.e. patients whose reproductive organs remain in place and who have not passed menopause) and men must agree to use a highly effective method of (e.g. hormonal, intrauterine device or; abstinence*) prior to study entry, during the study participation, and for six months after the last dose of the drug; women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to randomization, cannot be breast-feeding, and must agree to use a highly effective form of contraception throughout the treatment period and for 6 months after the last dose of study treatment; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

    • Abstinence is only acceptable when this is in line with the preferred and usual lifestyle of the patient
  • Patients must have the ability to understand and sign an approved and authorization permitting release of personal health information
  • Patients must have a GOG performance status of 0 or 1
  • Able to swallow and retain orally-administered medication and does not have any gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome, bowel obstruction, or major resection of the stomach or bowel
  • All prior treatment-related toxicities must be v4 grade =\< 1 (except alopecia) at the time of randomization
  • Patients must have a >= lower limit of normal by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
  • Serum creatinine =\< 1.5 mg/dL OR calculated (Cockcroft-Gault formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min (within 14 days prior to treatment)
  • =\< 1.5 times (within 14 days prior to treatment)
  • (ALT) =\< 2.5 times upper limit of normal (within 14 days prior to treatment)
  • Aspartate aminotransferase (AST) =\< 2.5 times upper limit of normal (within 14 days prior to treatment)
  • Albumin >= 2.5 g/dL (within 14 days prior to treatment)
  • (PT) and activated partial thromboplastin time (APTT) =\< 1.5 times upper limit of normal (within 14 days prior to treatment)
  • >= 1.5 x 10\^9/L (within 14 days prior to treatment)
  • count >= 100 x 10\^9/L (within 14 days prior to treatment)
  • >= 9.0 g/dL (within 14 days prior to treatment)
  • If letrozole is selected as the control therapy, patients must be , either following bilateral oophorectomy or at least 5 years after spontaneous menopause; patients within 5 years of spontaneous menopause or who have had a hysterectomy without bilateral oophorectomy must have postmenopausal luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels; patients on hormone replacement therapy (HRT) must agree to withdrawal of hormone therapy before letrozole is started

Exclusion criteria

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Use of other drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib or standard of care agent
  • If patients have had a potential index lesion radiated, it must have progressed post radiation therapy to be used as a measurable eligibility lesion
  • Patients may not have received prior MEK, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), or v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor therapy
  • Current use of a prohibited medication; the following medications or non-drug therapies are prohibited:

    • Patients may not be receiving any other anti-cancer or investigational agents
    • Because the composition, PK, and metabolism of many herbal supplements are unknown, the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to St. John's wort, kava, ephedra [ma huang], gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)
  • Patients with known or or spinal cord compression should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
  • Patients with a bowel obstruction or any other gastrointestinal condition that might affect absorption of the oral drug should be excluded; this would include patients with inability to swallow and retain orally-administered medication, malabsorption syndrome, or those with a major resection of the stomach or bowels
  • Patients with a history of interstitial lung disease or pneumonitis
  • Patients with a previous or current at other sites should be excluded, with the exception of:

    • Curatively treated local tumors such as carcinoma-in-situ of the cervix, basal or squamous cell carcinoma of the skin
    • Tumors for which no relapse has been observed within 5 years
  • Known virus (HBV), or virus (HCV) infection (patients with chronic or cleared HBV and HCV infection are eligible); patients with (HIV) are not eligible if on anti-retroviral medications
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to trametinib, or , or to dimethyl sulfoxide (DMSO), or to Cremophor EL (polyoxyethylated castor oil); please note, exclusion for Cremophor is unnecessary unless paclitaxel is the only agent available and the patient randomizes to the conventional therapy option
  • Patients with a history or evidence of cardiovascular risk, including any of the following:

    • (LVEF) \< lower limit of normal (LLN)
    • Bazett's (QTcB) >= 480 msec
    • History or evidence of current uncontrolled arrhythmias
    • Exception: Subjects with controlled atrial fibrillation for > 30 days prior to randomization are eligible
    • History of (within 6 months prior to randomization) acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting
    • History or evidence of current >= class II congestive heart failure as defined by (NYHA)
    • Treatment hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy
    • Patients with intra-cardiac defibrillators or permanent pacemakers
    • Known cardiac
  • Patients with a history or current evidence/risk of retinal vein occlusion (RVO)
  • Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining or compliance to the study procedures
  • Patients who require use of a concomitant medication that can prolong the QT interval
  • Animal reproductive studies have not been conducted with trametinib; therefore, the study drug must not be administered to pregnant women or nursing mothers; women of should be advised to avoid pregnancy and use effective methods of ; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
260 participants (actual)

Study arms

  • Active comparator
    Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)

    Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.

    Drug: Letrozole · Drug: Paclitaxel · Drug: Pegylated Liposomal Doxorubicin Hydrochloride · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Drug: Tamoxifen Citrate · Drug: Topotecan

  • Experimental
    Arm B (trametinib)

    Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Other: Quality-of-Life Assessment · Drug: Trametinib Dimethyl Sulfoxide

Interventions

  • Given PO

    Also known as: CGS 20267, CGS-20267, CGS20267, Femara, Fempro

  • Given IV

    Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

  • DrugLiposomal doxorubicinStudies of Liposomal doxorubicinLiposomal doxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

  • DrugTamoxifenStudies of TamoxifenTamoxifen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Gen-Tamoxifen, Genox, ICI 46,474, ICI 46474, ICI-46474, ICI46474, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex, Nolvadex-D, Nourytam, Novo-Tamoxifen, Novofen, Noxitem, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, TAM, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Tamoxifeni Citras, Zemide

  • Given IV

    Also known as: Hycamptamine, Topotecan Lactone

  • Given PO

    Also known as: Mekinist, Meqsel, Spexotras

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the PFS endpoint definition.

    Time frame: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy. Excludes AEs observed among control patients treated with trametinib after crossover.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the AE endpoint definition.

    Time frame: During treatment period and up to 100 days after stopping the study treatment

  2. Overall Survival

    Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact. Patients with disease progression on the Control arm were allowed to cross over to the trametinib arm. Per the protocol, the intent-to-treat OS analysis was not adjusted for crossover.

    Time frame: Time from study entry to time of death or date of last contact, an average of 29 months for arm A and 37 months for arm B

  3. Objective Tumor Response Rate (Complete Response and Partial Response)

    The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria.

    Time frame: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B

  4. Patients Reported Acute Quality of Life

    Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for ovarian cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). . The FACT-O TOI score is calculated as the sum of the subscale scores if more than 80% of the FACT-O TOI items provide valid answers and all of the component subscales have valid scores. The FACT-O TOI score ranges 0-100 with a large score suggesting better QOL. Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the quality of life endpoint definition

    Time frame: 1. baseline (prior to cycle 1), 12 weeks (prior to cycle 4), 24 weeks (4 weeks post cycle 6), 36 weeks post cycle 1, 52 weeks post cycle 1.

  5. Patient Reported Acute Peripheral Neuropathy Symptoms

    Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggesting less peripheral neuropathy symptoms

    Time frame: Up to 52 weeks

  6. Progression Free Survival

    Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan. RECIST v1.1 defines progression as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

    Time frame: Time from study entry to time of progression or death, an average of 7 months for SOC and 13 months for the treatment (Trametinib) arm.

  7. pERK Expression

    Will be quantified using the H-score derived from the immunohistochemistry analysis of patient tumor tissue and is expected to present as a continuous measure. will consider the prognostic and predictive abilities of pERK relative to objective response rate (ORR) or PFS. Analysis of the dichotomous markers will be supported by Kaplan Meier plots, and forest plots of the odds-ratio and hazard ratio estimates. Duration of response will be depicted using swimmer plots, with median duration estimated using Kaplan Meier methods. The multivariable models will include covariate adjustment for geographic region, performance status and number of prior regimens, presented using effect coding. The adjusted hazard- and odds- ratio estimates from the multivariable models will be supported by nominal p-values and 2-sided, 95% confidence intervals. Confidence intervals will be interpreted as the plausible range of values for the true (unobserved) ratio that is supported by the data.

    Time frame: Baseline

07

Results

Posted Sep 29, 2020
Limitations and caveats
The pERK expression analysis is still under development, and will not be available for approximately 2 - 3 years.

Participant flow

A total of 260 patients enrolled before accrual closed on 04/10/2018.

Participant flow — Overall Study
MilestoneArm A - Control ArmArm B - Experimental Arm
Started130130
Crossover from arm a to arm b880
Completed120116
Not completed1014

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the PFS endpoint definition.

Time frame:
Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B
Reported as:
Median · months
Progression-free Survival (PFS)
monthsArm A - Control ArmArm B - Experimental Arm
Progression-free Survival (PFS)7.2 (5.6 to 9.9)13.0 (9.9 to 15.0)
SecondaryIncidence of Adverse Events (AEs)

Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy. Excludes AEs observed among control patients treated with trametinib after crossover.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the AE endpoint definition.

Time frame:
During treatment period and up to 100 days after stopping the study treatment
Reported as:
Number · participants
Incidence of Adverse Events (AEs)
participantsArm A - Control ArmArm B - Experimental Arm
Abdominal pain227
Anemia1216
Diarrhea413
Fatigue510
Hypertension615
Nausea1412
Neutrophil count decreased18
Rash maculo-papular09
Small Intestinal Obstruction916
Vomiting109
SecondaryOverall Survival

Overall survival (OS) was defined as the number of months between study enrollment and death from any cause. Patients still alive at the last follow-up were censored on the date of last contact. Patients with disease progression on the Control arm were allowed to cross over to the trametinib arm. Per the protocol, the intent-to-treat OS analysis was not adjusted for crossover.

Time frame:
Time from study entry to time of death or date of last contact, an average of 29 months for arm A and 37 months for arm B
Reported as:
Median · Months
Overall Survival
MonthsArm A - Control ArmArm B - Experimental Arm
Overall Survival29.2 (23.5 to 51.6)37.0 (30.3 to —)
SecondaryObjective Tumor Response Rate (Complete Response and Partial Response)

The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria.

Time frame:
Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B
Reported as:
Number · participants
Objective Tumor Response Rate (Complete Response and Partial Response)
participantsArm A - Control ArmArm B - Experimental Arm
Objective Tumor Response Rate (Complete Response and Partial Response)834
SecondaryPatients Reported Acute Quality of Life

Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for ovarian cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). . The FACT-O TOI score is calculated as the sum of the subscale scores if more than 80% of the FACT-O TOI items provide valid answers and all of the component subscales have valid scores. The FACT-O TOI score ranges 0-100 with a large score suggesting better QOL. Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the quality of life endpoint definition

Time frame:
1. baseline (prior to cycle 1), 12 weeks (prior to cycle 4), 24 weeks (4 weeks post cycle 6), 36 weeks post cycle 1, 52 weeks post cycle 1.
Reported as:
Mean · score on a scale
Patients Reported Acute Quality of Life
score on a scaleArm A (Letrozole, Tamoxifen, Paclitaxel, PLD, Topotecan)Arm B (Trametinib)
Baseline74.5 ± 16.674.5 ± 13.7
12 Weeks74.2 ± 16.070.6 ± 13.5
24 Weeks70.2 ± 15.573.0 ± 12.8
36 Weeks69.3 ± 18.672.6 ± 12.8
52 Weeks72.1 ± 16.973.3 ± 14.3
SecondaryPatient Reported Acute Peripheral Neuropathy Symptoms

Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggesting less peripheral neuropathy symptoms

Time frame:
Up to 52 weeks
Reported as:
Mean · score on a scale
Patient Reported Acute Peripheral Neuropathy Symptoms
score on a scaleArm A (Letrozole, Tamoxifen, Paclitaxel, PLD, Topotecan)Arm B (Trametinib)
Baseline13.2 ± 3.512.8 ± 3.8
12 Weeks12.5 ± 4.012.6 ± 4.2
24 Weeks12.4 ± 4.012.1 ± 4.2
36 Weeks12.3 ± 3.812.6 ± 3.9
52 Weeks12.8 ± 3.212.4 ± 4.2
SecondaryProgression Free Survival

Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan. RECIST v1.1 defines progression as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.

Time frame:
Time from study entry to time of progression or death, an average of 7 months for SOC and 13 months for the treatment (Trametinib) arm.
Reported as:
Median · Months
Progression Free Survival
MonthsKRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (Trametinib)KRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (SOC)KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (Trametinib)KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (SOC)
Progression Free Survival13.2 (9.4 to 20.8)11.4 (3.7 to 13.3)7.3 (5.6 to 12.7)6.3 (3.7 to 9.9)
Statistical analysis
  • KRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (Trametinib) vs KRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (SOC) · Hazard ratio (hr): 0.55 · 95% CI 0.28 to 1.07Estimation of treatment effect; Trametinib vs. SOC among patients with a mutation.
  • KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (Trametinib) vs KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (SOC) · Hazard ratio (hr): 0.64 · 95% CI 0.39 to 1.03Estimation of treatment effect; Trametinib vs. SOC among wild-type patients.
  • KRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (SOC) vs KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (SOC) · Chi-squared · p = 0.0929 · Hazard ratio (hr): 0.60 · 95% CI 0.34 to 1.08Estimation of mutation effect; mutant vs. wild-type in the SOC group.
  • KRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (Trametinib) vs KRAS/BRAF/NRAS Mutant Group (MAPK Pathway) (SOC) vs KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (Trametinib) vs KRAS/BRAF/NRAS Wild-type (MAPK Pathway) (SOC) · Chi-squared · p = 0.7195
SecondarypERK Expression

Will be quantified using the H-score derived from the immunohistochemistry analysis of patient tumor tissue and is expected to present as a continuous measure. will consider the prognostic and predictive abilities of pERK relative to objective response rate (ORR) or PFS. Analysis of the dichotomous markers will be supported by Kaplan Meier plots, and forest plots of the odds-ratio and hazard ratio estimates. Duration of response will be depicted using swimmer plots, with median duration estimated using Kaplan Meier methods. The multivariable models will include covariate adjustment for geographic region, performance status and number of prior regimens, presented using effect coding. The adjusted hazard- and odds- ratio estimates from the multivariable models will be supported by nominal p-values and 2-sided, 95% confidence intervals. Confidence intervals will be interpreted as the plausible range of values for the true (unobserved) ratio that is supported by the data.

Time frame:
Baseline

Results for this outcome have not been posted.

Adverse events

Collected over Starting with the first treatment received, and ending 100 days after the last treatment, or at the last following, whichever is sooner. Time frame was approximately 30 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A - Control Arm60/127 (47.2%)43/127 (33.9%)124/127 (97.6%)
Arm B - Experimental Arm51/127 (40.2%)45/127 (35.4%)127/127 (100%)
Crossover From Control to Experimental Arm3/88 (3.4%)25/88 (28.4%)88/88 (100%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventArm A - Control ArmArm B - Experimental ArmCrossover From Control to Experimental Arm
Small Intestinal ObstructionGastrointestinal disorders2/12711/1273/88
Abdominal PainGastrointestinal disorders10/1272/1272/88
Colonic ObstructionGastrointestinal disorders4/1270/1275/88
Urinary Tract InfectionInfections and infestations4/1276/1272/88
NauseaGastrointestinal disorders5/1271/1270/88
AnemiaBlood and lymphatic system disorders1/1274/1271/88
Thromboembolic EventVascular disorders1/1274/1270/88
VomitingGastrointestinal disorders1/1273/1271/88
Vaginal HemorrhageReproductive system and breast disorders3/1270/1271/88
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/1272/1272/88
Most frequent other events
Showing 10 of 322
Most frequent other events
EventArm A - Control ArmArm B - Experimental ArmCrossover From Control to Experimental Arm
DiarrheaGastrointestinal disorders43/12792/12753/88
FatigueGeneral disorders75/12792/12759/88
Rash AcneiformSkin and subcutaneous tissue disorders13/12780/12750/88
NauseaGastrointestinal disorders65/12777/12748/88
AnemiaBlood and lymphatic system disorders54/12766/12751/88
Abdominal PainGastrointestinal disorders60/12756/12748/88
Edema LimbsGeneral disorders15/12761/12736/88
VomitingGastrointestinal disorders44/12758/12733/88
Dry SkinSkin and subcutaneous tissue disorders17/12756/12740/88
ConstipationGastrointestinal disorders49/12754/12731/88

Baseline characteristics

All enrolled patients.

Age, Continuous
Age, Continuous(years)Arm A - Control ArmArm B - Experimental ArmTotal
Mean53.89 ± 14.0353.57 ± 14.1353.7 ± 14.1
Age, Customized
Age, Customized(Participants)Arm A - Control ArmArm B - Experimental ArmTotal
20-29 years91019
30-39 years181634
40-49 years212243
50-59 years283563
60-69 years393372
>= 70 years151429
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - Control ArmArm B - Experimental ArmTotal
Female130130260
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A - Control ArmArm B - Experimental ArmTotal
Hispanic or Latino7815
Not Hispanic or Latino118118236
Unknown or Not Reported549
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A - Control ArmArm B - Experimental ArmTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander224
Black or African American549
White114115229
More than one race000
Unknown or Not Reported7714
Region of Enrollment
Region of Enrollment(participants)Arm A - Control ArmArm B - Experimental ArmTotal
United States102103205
United Kingdom282755
Number of Prior Treatment Regimens
Number of Prior Treatment Regimens(Participants)Arm A - Control ArmArm B - Experimental ArmTotal
1 Prior Treatment Regimens302959
2 Prior Treatment Regimens373976
3 or More Prior Treatment Regimens6362125
08

Study locations

501 sites
  • Tennessee Valley Gynecologic Oncology
    Huntsville, Alabama 35805, United States
  • Anchorage Associates in Radiation Medicine
    Anchorage, Alaska 98508, United States
  • Anchorage Radiation Therapy Center
    Anchorage, Alaska 99504, United States
  • Alaska Breast Care and Surgery LLC
    Anchorage, Alaska 99508, United States
  • Alaska Oncology and Hematology LLC
    Anchorage, Alaska 99508, United States
  • Alaska Women's Cancer Care
    Anchorage, Alaska 99508, United States
  • Anchorage Oncology Centre
    Anchorage, Alaska 99508, United States
  • Katmai Oncology Group
    Anchorage, Alaska 99508, United States
  • Providence Alaska Medical Center
    Anchorage, Alaska 99508, United States
  • Fairbanks Memorial Hospital
    Fairbanks, Alaska 99701, United States
  • Banner University Medical Center - Tucson
    Tucson, Arizona 85719, United States
  • University of Arizona Cancer Center-North Campus
    Tucson, Arizona 85719, United States
  • CHI Saint Vincent Cancer Center Hot Springs
    Hot Springs, Arkansas 71913, United States
  • Sutter Auburn Faith Hospital
    Auburn, California 95602, United States
  • Sutter Cancer Centers Radiation Oncology Services-Auburn
    Auburn, California 95603, United States
  • Alta Bates Summit Medical Center-Herrick Campus
    Berkeley, California 94704, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center
    Burbank, California 91505, United States
  • Mills-Peninsula Medical Center
    Burlingame, California 94010, United States
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
    Cameron Park, California 95682, United States
  • Eden Hospital Medical Center
    Castro Valley, California 94546, United States
  • Community Cancer Institute
    Clovis, California 93611, United States
  • University Oncology Associates
    Clovis, California 93611, United States
  • Sutter Davis Hospital
    Davis, California 95616, United States
  • Palo Alto Medical Foundation-Fremont
    Fremont, California 94538, United States
  • Memorial Medical Center
    Modesto, California 95355, United States
  • Palo Alto Medical Foundation-Camino Division
    Mountain View, California 94040, United States
  • Palo Alto Medical Foundation-Gynecologic Oncology
    Mountain View, California 94040, United States
  • Sutter Cancer Research Consortium
    Novato, California 94945, United States
  • Palo Alto Medical Foundation Health Care
    Palo Alto, California 94301, United States
  • Stanford Cancer Institute Palo Alto
    Palo Alto, California 94304, United States
  • Sutter Cancer Centers Radiation Oncology Services-Roseville
    Roseville, California 95661, United States
  • Sutter Roseville Medical Center
    Roseville, California 95661, United States
  • Sutter Medical Center Sacramento
    Sacramento, California 95816, United States
  • California Pacific Medical Center-Pacific Campus
    San Francisco, California 94115, United States
  • UCSF Medical Center-Mission Bay
    San Francisco, California 94158, United States
  • Stanford Cancer Center South Bay
    San Jose, California 95124, United States
  • Palo Alto Medical Foundation-Santa Cruz
    Santa Cruz, California 95065, United States
  • Sutter Pacific Medical Foundation
    Santa Rosa, California 95403, United States
  • Palo Alto Medical Foundation-Sunnyvale
    Sunnyvale, California 94086, United States
  • Sutter Solano Medical Center/Cancer Center
    Vallejo, California 94589, United States
  • Rocky Mountain Cancer Centers-Aurora
    Aurora, Colorado 80012, United States
  • The Medical Center of Aurora
    Aurora, Colorado 80012, United States
  • Boulder Community Foothills Hospital
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer Centers-Boulder
    Boulder, Colorado 80304, United States
  • Penrose-Saint Francis Healthcare
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers-Penrose
    Colorado Springs, Colorado 80907, United States
  • Denver Health Medical Center
    Denver, Colorado 80204, United States
  • National Jewish Health-Main Campus
    Denver, Colorado 80206, United States
  • The Women's Imaging Center
    Denver, Colorado 80209, United States
  • AdventHealth Porter
    Denver, Colorado 80210, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Presbyterian - Saint Lukes Medical Center - Health One
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers-Midtown
    Denver, Colorado 80218, United States
  • Saint Joseph Hospital - Cancer Centers of Colorado
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers-Rose
    Denver, Colorado 80220, United States
  • Rose Medical Center
    Denver, Colorado 80220, United States
  • Western States Cancer Research NCORP
    Denver, Colorado 80222, United States
  • CommonSpirit Cancer Center Mercy
    Durango, Colorado 81301, United States
  • Mercy Medical Center
    Durango, Colorado 81301, United States
  • Mountain Blue Cancer Care Center - Swedish
    Englewood, Colorado 80113, United States
  • Swedish Medical Center
    Englewood, Colorado 80113, United States
  • Mountain Blue Cancer Care Center
    Golden, Colorado 80401, United States
  • National Jewish Health-Western Hematology Oncology
    Golden, Colorado 80401, United States
  • Banner North Colorado Medical Center
    Greeley, Colorado 80631, United States
  • Rocky Mountain Cancer Centers-Greenwood Village
    Greenwood Village, Colorado 80111, United States
  • Rocky Mountain Cancer Centers-Lakewood
    Lakewood, Colorado 80228, United States
  • Saint Anthony Hospital
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers-Littleton
    Littleton, Colorado 80120, United States
  • AdventHealth Littleton
    Littleton, Colorado 80122, United States
  • Rocky Mountain Cancer Centers-Sky Ridge
    Lone Tree, Colorado 80124, United States
  • Sky Ridge Medical Center
    Lone Tree, Colorado 80124, United States
  • Longmont United Hospital
    Longmont, Colorado 80501, United States
  • Rocky Mountain Cancer Centers-Longmont
    Longmont, Colorado 80501, United States
  • Banner McKee Medical Center
    Loveland, Colorado 80539, United States
  • AdventHealth Parker
    Parker, Colorado 80138, United States
  • Rocky Mountain Cancer Centers-Parker
    Parker, Colorado 80138, United States
  • Saint Mary Corwin Medical Center
    Pueblo, Colorado 81004, United States
  • Rocky Mountain Cancer Centers - Pueblo
    Pueblo, Colorado 81008, United States
  • National Jewish Health-Northern Hematology Oncology
    Thornton, Colorado 80260, United States
  • Rocky Mountain Cancer Centers-Thornton
    Thornton, Colorado 80260, United States
  • Intermountain Health Lutheran Hospital
    Wheat Ridge, Colorado 80401, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Smilow Cancer Hospital Care Center at Saint Francis
    Hartford, Connecticut 06105, United States
  • The Hospital of Central Connecticut
    New Britain, Connecticut 06050, United States
  • Sibley Memorial Hospital
    Washington D.C., District of Columbia 20016, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables
    Coral Gables, Florida 33146, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
  • Jackson Memorial Hospital-Holtz Children's Hospital
    Miami, Florida 33136, United States
  • University of Miami Miller School of Medicine-Sylvester Cancer Center
    Miami, Florida 33136, United States
  • UM Sylvester Comprehensive Cancer Center at Plantation
    Plantation, Florida 33324, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • John B Amos Cancer Center
    Columbus, Georgia 31904, United States
  • Northside Hospital-Forsyth
    Cumming, Georgia 30041, United States
  • Northeast Georgia Medical Center-Gainesville
    Gainesville, Georgia 30501, United States
  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    Savannah, Georgia 31405, United States
  • Saint Alphonsus Cancer Care Center-Boise
    Boise, Idaho 83706, United States
  • Saint Luke's Cancer Institute - Boise
    Boise, Idaho 83712, United States
  • Saint Alphonsus Cancer Care Center-Caldwell
    Caldwell, Idaho 83605, United States
  • Kootenai Health - Coeur d'Alene
    Coeur d'Alene, Idaho 83814, United States
  • Walter Knox Memorial Hospital
    Emmett, Idaho 83617, United States

Showing the first 100 of 501 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9. PubMed 35123694 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Apr 2019, 59 months.

Results were first posted in Sep 2020, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2014
First posted
Apr 2, 2014
StartActual
Apr 11, 2014
Primary completionActual
Apr 4, 2019
CompletionActual
Oct 27, 2025
Results first posted
Sep 29, 2020
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02101788
Collaborators
NRG Oncology
Responsible party
Sponsor
First posted
Apr 2, 2014
Start date
Apr 11, 2014
Primary completion
Apr 4, 2019
Completion
Oct 27, 2025
Results posted
Sep 29, 2020
Last update
Aug 4, 2026

Study contacts

David M Gershenson
principal investigator · NRG Oncology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trametinib dimethyl sulfoxide

Start the discussion